Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was the target of some unusual options trading activity on Monday. Traders purchased 946 put options on the company. This represents an increase of 827% compared to the average volume of 102 put options.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at $13.35 on Thursday. Momenta Pharmaceuticals has a 12-month low of $11.85 and a 12-month high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million for the quarter, compared to analyst estimates of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business’s quarterly revenue was down 17.3% on a year-over-year basis. During the same period last year, the business posted ($0.26) EPS. equities research analysts predict that Momenta Pharmaceuticals will post -1.16 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the stock. Barclays reiterated an “equal weight” rating and issued a $16.00 target price (down from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and issued a $14.00 price target (down from $18.00) on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. BidaskClub lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. Finally, J P Morgan Chase & Co restated a “hold” rating and issued a $14.00 price target on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $15.00.

In related news, President Craig A. Wheeler sold 35,667 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total value of $678,743.01. Following the transaction, the president now directly owns 286,121 shares in the company, valued at approximately $5,444,882.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 44,006 shares of company stock worth $789,369 over the last quarter. 4.40% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of MNTA. BlackRock Inc. boosted its position in shares of Momenta Pharmaceuticals by 7.1% during the 2nd quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock valued at $158,868,000 after acquiring an additional 626,415 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Momenta Pharmaceuticals by 186.4% during the 2nd quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock valued at $13,476,000 after acquiring an additional 519,000 shares in the last quarter. FMR LLC boosted its position in shares of Momenta Pharmaceuticals by 3.3% during the 2nd quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock valued at $188,015,000 after acquiring an additional 351,743 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Momenta Pharmaceuticals by 102.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 691,778 shares of the biotechnology company’s stock valued at $11,691,000 after acquiring an additional 350,112 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Momenta Pharmaceuticals by 4.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock valued at $105,519,000 after acquiring an additional 290,090 shares in the last quarter. Institutional investors and hedge funds own 93.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Traders Purchase High Volume of Put Options on Momenta Pharmaceuticals (MNTA)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/14/traders-purchase-high-volume-of-put-options-on-momenta-pharmaceuticals-mnta.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Receive News & Stock Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related stocks with our FREE daily email newsletter.